{"schema_version":"secwatch.filing_event.v1","accession":"0001285550-24-000049","form_type":"8-K","ticker":"CLPT","cik":"0001285550","company_name":"ClearPoint Neuro, Inc.","filed_at":"2024-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.711691+00:00","generated_at":"2026-06-02T16:35:22.568417+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"ClearPoint Neuro Q1 revenue $7.6M (+41% YoY); biologics revenue $4.3M (+61%); cash burn down 32%","bullets":["Record quarterly revenue of $7.6M, up 41% YoY; biologics/drug delivery revenue up 61% to $4.3M.","Capital equipment sales surged 255% to $1.4M; SmartFrame OR received 510(k) clearance and first clinical cases performed.","Activated 8 new hospital sites in Q1, a company record, bringing total active sites to over 80.","Operational cash burn reduced 32% to $3.8M; cash and equivalents totaled $35.4M after $16.2M public offering.","Reaffirmed FY2024 revenue outlook of $28M-$32M; first-ever neuro gene therapy BLA submitted by partner PTC Therapeutics."],"urls":{"canonical":"https://secwatch.observer/filing/0001285550-24-000049","json":"https://secwatch.observer/filing/0001285550-24-000049.json","markdown":"https://secwatch.observer/filing/0001285550-24-000049.md","text":"https://secwatch.observer/filing/0001285550-24-000049.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/0001285550-24-000049-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/clpt-20240507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T16:35:22.568417+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"03c6f8b9a1e21a2f59f7c53117f3b148b1596e43","claim":"ClearPoint Neuro, Inc. reported the first quarter ended March 31, 2024 results: revenue $7.6 million. Guidance reaffirmed.","evidence_excerpt":"precise navigation to the brain and spine, today announced financial results for its first quarter ended March 31, 2024. First Quarter Highlights • Reported quarterly revenue of $7.6 million, a 41% year-over-year increase; • Increased biologics and drug delivery revenue to $4.3 million, a 61% year-over-year increase; • Partner PTC Therapeutics submitted first-ever","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1285550/000128555024000049/0001285550-24-000049-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Revenue","value":"$7.6 million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}